- Home
- TXMD vs RVPHW Comparison
TXMD vs RVPHW Comparison
Compare TXMD & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- RVPHW
- Stock Information
- Founded
- TXMD 2008
- RVPHW 2018
- Country
- TXMD United States
- RVPHW United States
- Employees
- TXMD N/A
- RVPHW 14
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- RVPHW Health Care
- Exchange
- TXMD Nasdaq
- RVPHW Nasdaq
- Market Cap
- TXMD N/A
- RVPHW N/A
- IPO Year
- TXMD N/A
- RVPHW N/A
- Fundamental
- Price
- TXMD $1.10
- RVPHW $0.06
- Analyst Decision
- TXMD
- RVPHW
- Analyst Count
- TXMD 0
- RVPHW 0
- Target Price
- TXMD N/A
- RVPHW N/A
- AVG Volume (30 Days)
- TXMD 39.8K
- RVPHW 22.4K
- Earning Date
- TXMD 05-13-2025
- RVPHW 03-14-2025
- Dividend Yield
- TXMD N/A
- RVPHW N/A
- EPS Growth
- TXMD N/A
- RVPHW N/A
- EPS
- TXMD N/A
- RVPHW N/A
- Revenue
- TXMD $1,841,000.00
- RVPHW N/A
- Revenue This Year
- TXMD $427.09
- RVPHW N/A
- Revenue Next Year
- TXMD N/A
- RVPHW N/A
- P/E Ratio
- TXMD N/A
- RVPHW N/A
- Revenue Growth
- TXMD 53.55
- RVPHW N/A
- 52 Week Low
- TXMD $0.70
- RVPHW $0.13
- 52 Week High
- TXMD $2.44
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- TXMD 32.08
- RVPHW N/A
- Support Level
- TXMD $1.43
- RVPHW N/A
- Resistance Level
- TXMD $1.51
- RVPHW N/A
- Average True Range (ATR)
- TXMD 0.10
- RVPHW 0.00
- MACD
- TXMD -0.04
- RVPHW 0.00
- Stochastic Oscillator
- TXMD 8.33
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.